Clovis Oncology commencing $250 million stock offering

One day after announcing good results of a trial of its ovarian cancer drug rucaparib, Clovis Oncology Inc. said it's commencing a $250 million public offering of its stock. The Boulder biotech said in a statement that it "intends to use the net proceeds of the offering for general corporate purposes, including sales and marketing expenses associated with rucaparib in the United States and, if approved by the European Medicines Agency (EMA), in Europe, funding of its development programs, general… (Source: bizjournals.com Health Care:Physician Practices headlines)

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2tJuiu8
via IFTTT